FREE SHIPPING ON ORDERS OVER $150

glp 1 oral drug Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Pill Delivers Injection-Like

$26.49

Quantity
- +
Description

*Correspondence: Salvatore Corrao, [email protected]

glp 1 oral drug Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Pill Delivers Injection-Like

In recent years, peptide-based medicines have transformed how we approach these challenges

glp 1 oral drug Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Pill Delivers Injection-Like

Novo Nordisk is the market leader: Ozempic (weekly injection for type 2 diabetes) Wegovy (higher-dose weekly injection for obesity) Rybelsus ( Oral tablets for diabetes Oral tablets for weight management is in phase 3 trials) Eli Lilly is the other major player: Mounjaro (weekly injection for type 2 diabetes) Zepbound (higherdose weekly injection for obesity) This duopoly meant that both stocks had an incredible run-up from 2020 to 2024

glp 1 oral drug Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Pill Delivers Injection-Like

Moore, Edie, Abram

glp 1 oral drug Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Pill Delivers Injection-Like

You may also like

TrimRX

US$ 28.03

4.9 (18 reviews)

recommand products